<s>
The_AT diagnostic_JJ tool_NN1 I_PPIS1 will_VM be_VBI analysing_VVG for_IF this_DD1 assignment_NN1 is_VBZ the_AT thrombelastograph_NN1 or_CC TEG_NP1 (_( Haemoscope_NP1 ,_, Illinois_NP1 ,_, USA_NP1 )_) ._. 
</s>
<s>
This_DD1 is_VBZ a_AT1 point-of-care_JJ test_NN1 for_IF coagulation_NN1 currently_RR in_II use_NN1 in_II cardiothoracic_JJ surgery_NN1 and_CC intensive_JJ care_NN1 in_II the_AT hospital_NN1 in_II which_DDQ I_PPIS1 work_VV0 ,_, and_CC which_DDQ is_VBZ increasingly_RR being_VBG asked_VVN for_IF by_II anaesthetists_NN2 during_II other_JJ types_NN2 of_IO surgery_NN1 ,_, such_II21 as_II22 aortic_JJ aneurysm_NN1 repair_NN1 ,_, radical_JJ neck_NN1 dissection_NN1 with_IW insertion_NN1 of_IO free_JJ flap_NN1 and_CC other_JJ surgery_NN1 with_IW the_AT potential_NN1 for_IF large_JJ blood_NN1 losses_NN2 or_CC haemostatic_JJ disturbance_NN1 ._. 
</s>
<s>
In_II these_DD2 circumstances_NN2 ,_, TEG_NP1 is_VBZ requested_VVN in_BCL21 order_BCL22 to_TO assess_VVI whether_CSW any_DD coagulopathy_NN1 is_VBZ present_JJ during_II and_CC after_II surgery_NN1 ,_, particularly_RR in_BCL21 order_BCL22 to_TO determine_VVI whether_CSW bleeding_VVG is_VBZ occurring_VVG because_II21 of_II22 a_AT1 disturbance_NN1 in_II haemostasis_NN1 or_CC from_II a_AT1 physical/surgical_JJ cause_NN1 (_( such_II21 as_II22 untied_JJ blood_NN1 vessel_NN1 )_) ._. 
</s>
<s>
Because_CS my_APPGE clinical_JJ area_NN1 does_VDZ not_XX directly_RR finance_VVI a_AT1 TEG_NN1 machine_NN1 ,_, I_ZZ1% and_CC my_APPGE colleagues_NN2 are_VBR not_XX trained_VVN to_TO perform_VVI the_AT test_NN1 ,_, and_CC so_RR must_VM request_VVI it_PPH1 from_II another_DD1 area_NN1 ._. 
</s>
<s>
Should_VM this_DD1 change_VVI ,_, we_PPIS2 would_VM be_VBI reasonably_RR expected_VVN to_TO gain_VVI competence_NN1 in_II taking_VVG samples_NN2 and_CC performing_VVG the_AT test_NN1 ._. 
</s>
<s>
Senior_JJ practitioners_NN2 (_( such_II21 as_II22 myself_PPX1 )_) would_VM be_VBI expected_VVN to_TO become_VVI experienced_JJ and_CC competent_JJ in_II the_AT analysis/interpretation_NN1 of_IO TEG_NN1 results_NN2 ,_, as_CSA we_PPIS2 are_VBR with_IW arterial_JJ blood_NN1 gas_NN1 analysis_NN1 results_NN2 ,_, and_CC as_RG senior_JJ practitioners_NN2 in_II areas_NN2 already_RR using_VVG TEG_NP1 do_VD0 ._. 
</s>
<s>
In_II this_DD1 assignment_NN1 I_PPIS1 will_VM briefly_RR discuss_VVI the_AT scientific_JJ principles_NN2 of_IO haemostasis_NN1 ,_, the_AT TEG_NN1 and_CC what_DDQ it_PPH1 measures_VVZ ._. 
</s>
<s>
I_PPIS1 will_VM discuss_VVI any_DD evidence_NN1 for_IF its_APPGE use_NN1 ,_, relevance_NN1 and_CC accuracy_NN1 ,_, and_CC any_DD advantages_NN2 or_CC disadvantages_NN2 over_II standard_JJ coagulation_NN1 tests_NN2 ,_, in_II31 relation_II32 to_II33 assessment_NN1 of_IO perioperative_JJ coagulopathy_NN1 and_CC transfusion_NN1 requirements_NN2 ._. 
</s>
<s>
Literature_NN1 searches_NN2 were_VBDR performed_VVN using_VVG Ovid_JJ Online_JJ ,_, ProQuest_NP1 and_CC the_AT National_JJ Electronic_JJ Library_NN1 for_IF Health_NN1 ._. 
</s>
<s>
Haemostasis_NN1 is_VBZ the_AT continual_JJ process_NN1 by_II which_DDQ the_AT body_NN1 controls_NN2 bleeding_VVG as_II a_AT1 result_NN1 of_IO everyday_JJ injury_NN1 to_II small_JJ blood_NN1 vessels_NN2 (_( e.g._REX from_II mechanical_JJ stresses_NN2 ,_, trauma_NN1 )_) and_CC larger_JJR injury_NN1 from_II surgical/medical_JJ interventions_NN2 and_CC major_JJ trauma_NN1 ._. 
</s>
<s>
Injury_NN1 to_II a_AT1 vessel_NN1 exposes_VVZ blood_NN1 to_II subendothelial_JJ collagen_NN1 and_CC substances_NN2 (_( such_II21 as_II22 adenosine_NN1 triphosphate_NN1 ,_, ADP_NN1 )_) released_VVN by_II damaged_JJ cells_NN2 ._. 
</s>
<s>
These_DD2 activate_VV0 platelets_NN2 ,_, causing_VVG them_PPHO2 to_TO adhere_VVI to_II the_AT vessel_NN1 wall_NN1 and_CC aggregate_JJ to_TO form_VVI a_AT1 platelet-rich_JJ haemostatic_JJ plug_NN1 which_DDQ occludes_VVZ the_AT vessel_NN1 and_CC arrests_NN2 bleeding_VVG within_II minutes_NNT2 (_( 1_MC1 o_ZZ1 haemostasis_NN1 )_) ._. 
</s>
<s>
Blood_NN1 coagulation_NN1 factors_NN2 are_VBR simultaneously_RR activated_VVN ,_, mainly_RR by_II exposure_NN1 of_IO blood_NN1 to_II tissue_NN1 factor_NN1 ,_, which_DDQ activates_VVZ factor_NN1 VII_MC ._. 
</s>
<s>
The_AT various_JJ coagulation_NN1 factors_NN2 interact_VV0 on_II the_AT surfaces_NN2 of_IO platelets_NN2 and_CC other_JJ cells_NN2 to_TO generate_VVI thrombin_NN1 from_II prothrombin_NN1 ._. 
</s>
<s>
Thrombin_NN1 converts_NN2 circulating_VVG fibrinogen_NN1 to_II fibrin_NN1 ,_, which_DDQ stabilises_VVZ the_AT initial_JJ platelet_NN1 plug_NN1 ,_, preventing_VVG secondary_JJ haemorrhage_NN1 (_( 2_MC o_ZZ1 haemostasis_NN1 )_) ._. 
</s>
<s>
Thrombin_NN1 also_RR generates_VVZ further_JJR coagulation_NN1 by_II activation_NN1 of_IO factors_NN2 V_ZZ1 and_CC VIII_MC ,_, and_CC activates_VVZ factor_NN1 XIII_MC which_DDQ both_DB2 cross-links_NN2 fibrin_NN1 to_TO increase_VVI its_APPGE resistance_NN1 to_II the_AT fibrinolytic_JJ system_NN1 and_CC inhibits_VVZ fibrinolysis_NN1 through_II thrombin_NN1 activated_VVD fibrinolytic_JJ inhibitor_NN1 (_( TAFI_NP1 )_) ._. 
</s>
<s>
In_II parallel_NN1 with_IW tissue_NN1 repair_NN1 ,_, the_AT fibrin_NN1 plug_NN1 is_VBZ then_RT broken_VVN down_RP over_II several_DA2 days_NNT2 ;_; tissue-type_JJ plasminogen_NN1 activator_NN1 activates_VVZ plasminogen_NN1 to_II plasmin_NN1 ,_, which_DDQ degrades_VVZ fibrin_NN1 to_II fibrin_NN1 degradation_NN1 products_NN2 (_( FDP_NP1 )_) such_II21 as_II22 fibrin_NN1 D-dimer_NN1 ._. 
</s>
<s>
Thrombelastography_NN1 was_VBDZ first_MD described_VVN by_II Hartert_NP1 in_II 1948_MC ._. 
</s>
<s>
A_AT1 pin_NN1 is_VBZ freely_RR suspended_VVN in_II a_AT1 warmed_JJ (_( to_II 37_MC oC_NN1 )_) cylindrical_JJ cup_NN1 by_II a_AT1 torsion_NN1 wire_NN1 connected_VVN to_II a_AT1 transducer_NN1 ._. 
</s>
<s>
The_AT cup_NN1 oscillates_VVZ around_II this_DD1 through_II an_AT1 angle_NN1 of_IO 4_MC o_ZZ1 -_- 45_MC o_ZZ1 for_IF ten_MC seconds_NNT2 ,_, mimicking_VVG sluggish_JJ blood_NN1 flow_NN1 (_( see_VV0 diagram_NN1 ,_, accessed_VVN 12/04/2006_MF )_) ._. 
</s>
<s>
A_ZZ1 360ul_FO whole_JJ blood_NN1 sample_NN1 is_VBZ added_VVN to_II the_AT cup_NN1 and_CC as_II the_AT clot_NN1 forms_VVZ the_AT cup_NN1 and_CC pin_NN1 become_VV0 linked_VVN together_RL ,_, causing_VVG the_AT previously_RR static_JJ pin_NN1 to_TO rotate_VVI more_RRR as_II the_AT clot_NN1 becomes_VVZ stronger_JJR and_CC then_RT less_RRR as_II clot_NN1 lysis_NN1 occurs_VVZ ._. 
</s>
<s>
The_AT rotational_JJ changes_NN2 are_VBR monitored_VVN by_II the_AT TEG_NN1 system_NN1 and_CC the_AT software_NN1 then_RT displays_VVZ them_PPHO2 both_DB2 graphically_RR and_CC as_II a_AT1 numerical_JJ assessment_NN1 of_IO the_AT patient_NN1 's_GE haemostatic_JJ function_NN1 ,_, showing_VVG time_NNT1 to_II initial_JJ clot_NN1 formation_NN1 (_( R_ZZ1 )_) ,_, time_NNT1 to_II maximum_JJ clot_NN1 strength_NN1 (_( MA_NP1 )_) ,_, clot_VV0 retraction_NN1 and_CC lysis_NN1 (_( A_ZZ1 30_MC )_) ._. 
</s>
<s>
The_AT TEG_NN1 trace_NN1 advances_VVZ at_II a_AT1 rate_NN1 of_IO 2mm/minute_FU and_CC so_RR parameters_NN2 are_VBR expressed_VVN in_II mm_NNU ._. 
</s>
<s>
(_( See_VV0 table_NN1 below_RL for_IF definition_NN1 of_IO parameters_NN2 )_) ._. 
</s>
<s>
Advancements_NN2 in_II the_AT system_NN1 software_NN1 now_RT also_RR allow_VV0 automated_JJ interpretation_NN1 of_IO results_NN2 ._. 
</s>
<s>
The_AT physical_JJ viscoelastic_JJ properties_NN2 of_IO the_AT clot_NN1 are_VBR dependent_JJ on_II the_AT interaction_NN1 of_IO fibrinogen_NN1 ,_, platelets_NN2 and_CC plasma_NN1 proteins_NN2 (_( Vig_NP1 et_RA21 al_RA22 2001_MC )_) ,_, and_CC so_RR can_VM be_VBI used_VVN to_TO pinpoint_VVI any_DD abnormality_NN1 in_II a_AT1 patient_NN1 's_GE particular_JJ haemostatic_JJ component_NN1 or_CC group_NN1 of_IO components_NN2 ._. 
</s>
<s>
In_II simple_JJ terms_NN2 ,_, the_AT stronger_JJR the_AT clot_NN1 formed_VVD the_AT greater_JJR the_AT torque_NN1 applied_VVN to_II the_AT pin_NN1 and_CC the_AT wider_JJR the_AT TEG_NN1 trace_NN1 will_VM be_VBI ;_; weak_JJ clots_NN2 will_VM stretch_VVI so_RR the_AT torque_NN1 will_VM be_VBI less_RRR and_CC the_AT trace_NN1 will_VM be_VBI narrower_JJR ._. 
</s>
<s>
Different_JJ traces_NN2 are_VBR characteristic_JJ of_IO different_JJ coagulopathies_NN2 and_CC in_II31 addition_II32 to_II33 being_VBG interpreted_VVN automatically_RR by_II the_AT TEG_NN1 software_NN1 ,_, practitioners_NN2 experienced_VVN in_II the_AT use_NN1 of_IO TEG_NP1 also_RR develop_VV0 a_AT1 high_JJ degree_NN1 of_IO interpretative_JJ skill_NN1 (_( Von_NP1 Kier_NP1 &;_NULL Parker_NP1 2001_MC )_) ._. 
</s>
<s>
The_AT Haemoscope_NN1 website_NN1 (_( )_) states_VVZ "_" The_AT TEG_NN1 system_NN1 is_VBZ unique_JJ in_II its_APPGE ability_NN1 to_TO detect_VVI the_AT state_NN1 ,_, cause_VV0 ,_, and_CC the_AT extent_NN1 of_IO imbalance_NN1 in_II patient_JJ hemostasis_NN1 and_CC in_II providing_VVG guidance_NN1 to_II effective_JJ treatment_NN1 ._. "_" ,_, 
</s>
<s>
and_CC markets_NN2 the_AT system_NN1 as_II a_AT1 means_NN of_IO rapid_JJ monitoring_NN1 of_IO haemostasis_NN1 at_II the_AT point_NN1 of_IO care_NN1 ._. 
</s>
<s>
The_AT main_JJ patient_JJ groups_NN2 on_II whom_PNQO TEG_NP1 is_VBZ currently_RR used_VVN are_VBR surgical_JJ and_CC critical_JJ care_NN1 patients_NN2 (_( Mallett_NP1 &;_NULL Cox_NP1 1992_MC ,_, McKenzie_NP1 et_RA21 al_RA22 1999_MC ,_, Liu_NP1 et_RA21 al_RA22 2000_MC ,_, Vig_NP1 et_RA21 al_RA22 2001_MC ,_, Prisco_NP1 &;_NULL Paniccia_NP1 2003_MC ,_, Samama_NP1 &;_NULL Ozier_NP1 2003_MC ,_, Ward_NP1 et_RA21 al_RA22 2004_MC and_CC Ward_NP1 &;_NULL Lewis_NP1 2004_MC )_) although_CS in_II a_AT1 review_NN1 ,_, Luddington_NP1 (_( 2005_MC )_) discusses_VVZ evidence_NN1 from_II studies_NN2 using_VVG TEG_NN1 to_II diagnoses_NN2 coagulopathies_NN2 in_II pregnancy_NN1 ,_, recurrent_JJ miscarriage_NN1 and_CC in_II noenates_NN2 ._. 
</s>
<s>
Historically_RR ,_, thrombelastography_NN1 was_VBDZ first_MD used_VVD clinically_RR for_IF haemostatic_JJ monitoring_NN1 during_II liver_NN1 transplantation_NN1 ,_, as_CSA described_VVN by_II Kang_NP1 et_RA21 al_RA22 (_( 1985_MC )_) ._. 
</s>
<s>
Of_IO particular_JJ interest_NN1 to_II clinicians_NN2 has_VHZ been_VBN the_AT use_NN1 of_IO TEG_NN1 to_TO determine_VVI if_CSW poor_JJ coagulation_NN1 function_NN1 during_II liver_NN1 transplantation_NN1 is_VBZ the_AT result_NN1 of_IO heparin/a_FU heparin-like_JJ effect_NN1 ,_, and_CC if_CS the_AT effect_NN1 is_VBZ reversed_VVN by_II protamine_NN1 ,_, which_DDQ several_DA2 studies_NN2 have_VH0 found_VVN to_TO be_VBI the_AT case_NN1 (_( Harding_NP1 et_RA21 al_RA22 1997_MC )_) ._. 
</s>
<s>
This_DD1 effect_NN1 had_VHD been_VBN causing_VVG difficulties_NN2 in_II the_AT field_NN1 for_IF some_DD time_NNT1 ,_, and_CC the_AT reason_NN1 for_IF it_PPH1 was_VBDZ not_XX known_VVN ._. 
</s>
<s>
Although_CS Harding_NP1 et_RA21 al_RA22 successfully_RR used_JJ TEG_NN1 to_TO improve_VVI clinical_JJ outcome_NN1 and_CC reduce_VVI blood_NN1 product_NN1 transfusion_NN1 ,_, a_AT1 modified_JJ TEG_NN1 assay_NN1 (_( using_VVG heparinase-coated_JJ cups_NN2 )_) was_VBDZ used_VVN and_CC the_AT sample_NN1 group_NN1 was_VBDZ relatively_RR small_JJ (_( 55_MC patients_NN2 )_) ._. 
</s>
<s>
Although_CS the_AT modified_JJ cups_NN2 are_VBR available_JJ from_II Haemoscope_NP1 ,_, this_DD1 variation_NN1 means_VVZ the_AT positive_JJ clinical_JJ outcome_NN1 in_II this_DD1 case_NN1 may_VM not_XX be_VBI used_VVN to_TO support_VVI the_AT likelihood_NN1 of_IO a_AT1 similar_JJ outcome_NN1 using_VVG plain/standard_JJ TEG_NN1 or_CC other_JJ modifications_NN2 to_TO guide_VVI treatment_NN1 ._. 
</s>
<s>
Haemostasis_NN1 during_II liver_NN1 transplantation_NN1 ,_, particularly_RR orthotopic_JJ transplantation_NN1 ,_, is_VBZ complex_JJ because_II21 of_II22 the_AT major_JJ surgery_NN1 involved_VVD ,_, the_AT anhepatic_JJ phase_NN1 and_CC the_AT disturbance_NN1 in_II haemostasis_NN1 caused_VVN by_II the_AT preoperative_JJ liver_NN1 dysfunction_NN1 ,_, and_CC is_VBZ not_XX yet_RR fully_RR understood_VVN (_( Luddington_NP1 2005_MC )_) ._. 
</s>
<s>
The_AT complex_JJ nature_NN1 of_IO the_AT disturbance_NN1 of_IO haemostatic_JJ function_NN1 has_VHZ not_XX always_RR been_VBN fully_RR expressed_VVN or_CC defined_VVN by_II disturbances_NN2 in_II commonly_RR used_JJ tests_NN2 of_IO coagulation_NN1 such_II21 as_II22 prothrombin_NN1 time_NNT1 (_( PTT_NP1 )_) ,_, activated_VVD partial_JJ thromboplastin_NN1 time_NNT1 (_( aPTT_NN1 )_) ,_, international_JJ ratio_NN1 (_( INR_NP1 )_) etc_RA ,_, (_( Mallett_NP1 &;_NULL Cox_NP1 1992_MC )_) not_XX least_RRT because_II21 of_II22 the_AT time_NNT1 lag_NN1 between_II blood_NN1 sampling_NN1 and_CC production_NN1 of_IO a_AT1 laboratory_NN1 result_NN1 ,_, which_DDQ may_VM easily_RR be_VBI more_DAR than_CSN an_AT1 hour_NNT1 (_( Samama_NP1 &;_NULL Ozier_NP1 2003_MC )_) ._. 
</s>
<s>
Achieving_VVG normal_JJ haemostatic_JJ function_NN1 is_VBZ vital_JJ for_IF the_AT success_NN1 of_IO the_AT transplant_NN1 ,_, and_CC running_VVG regular_JJ TEG_NN1 samples_NN2 has_VHZ been_VBN used_VVN to_TO identify_VVI qualitative_JJ disturbances_NN2 in_II haemostasis_NN1 quickly_RR so_CS they_PPHS2 can_VM be_VBI acted_VVN on_II appropriately_RR ._. 
</s>
<s>
The_AT other_JJ surgical_JJ field_NN1 in_II which_DDQ TEG_NP1 has_VHZ been_VBN used_VVN extensively_RR is_VBZ that_DD1 of_IO cardiac_JJ surgery_NN1 ._. 
</s>
<s>
Patients_NN2 undergoing_VVG cardiac_JJ surgery_NN1 are_VBR often_RR placed_VVN on_II cardiopulmonary_JJ bypass_NN1 (_( CPB_NP1 )_) ,_, which_DDQ induces_VVZ complex_JJ disturbances_NN2 in_II the_AT coagulation_NN1 and_CC fibrinolytic_JJ systems_NN2 ,_, particularly_RR in_II31 relation_II32 to_II33 platelet_NN1 function_NN1 (_( Mallett_NP1 &;_NULL Cox_NP1 ,_, 1992_MC )_) ,_, because_II21 of_II22 the_AT exposure_NN1 of_IO circulating_VVG blood_NN1 to_II the_AT 'foreign'_JJ surfaces_NN2 of_IO the_AT CPB_NP1 equipment_NN1 ._. 
</s>
<s>
Routine_NN1 coagulation_NN1 tests_NN2 do_VD0 not_XX assess_VVI the_AT resulting_JJ alteration_NN1 in_II the_AT interactions_NN2 between_II platelets_NN2 and_CC the_AT coagulation_NN1 cascade_NN1 ,_, merely_RR whether_CSW platelets_NN2 are_VBR present_JJ (_( platelet_NN1 count_NN1 )_) and_CC time_NNT1 to_II initial_JJ fibrin_NN1 formation_NN1 (_( activated_VVN clotting_VVG time_NNT1 ,_, ACT_NN1 )_) ._. 
</s>
<s>
No_AT information_NN1 is_VBZ gained_VVN about_II platelet-fibrin_JJ interactions_NN2 or_CC physical_JJ properties_NN2 of_IO the_AT clot_NN1 ,_, both_DB2 of_IO which_DDQ are_VBR affected_VVN by_II CPB_NP1 ._. 
</s>
<s>
Old_JJ studies_NN2 (_( Spiess_NP1 et_RA21 al_RA22 1987_MC )_) have_VH0 shown_VVN that_CST TEG_NP1 had_VHD 87%_NNU accuracy_NN1 in_II predicting_VVG post-operative_JJ haemorrhage_NN1 and_CC need_VV0 for_IF re-operation_NN1 ,_, as_CSA compared_VVN to_II ACT_NN1 which_DDQ had_VHD 30%_NNU accuracy_NN1 ,_, and_CC conventional_JJ coagulation_NN1 tests_NN2 which_DDQ had_VHD 51%_NNU accuracy_NN1 ._. 
</s>
<s>
The_AT use_NN1 of_IO TEG_NN1 as_II a_AT1 predictor_NN1 of_IO post_NN1 bypass_NN1 coagulopathy_NN1 and_CC use_NN1 of_IO a_AT1 TEG_NN1 guided_JJ algorithm_NN1 for_IF management_NN1 of_IO post-bypass_JJ bleeding_JJ has_VHZ been_VBN found_VVN by_II several_DA2 studies_NN2 to_TO significantly_RR reduce_VVI transfusion_NN1 requirements_NN2 (_( Spiess_NP1 et_RA21 al_RA22 1995_MC ,_, Shore-Lesserson_NP1 et_RA21 al_RA22 1999_MC ,_, Bell_NP1 ,_, Anderson_NP1 &;_NULL Macfie_NP1 2001_MC ,_, Royston_NP1 &;_NULL Von_NP1 Kier_NP1 2001_MC ,_, Samama_NP1 &;_NULL Ozier_NP1 2003_MC )_) ._. 
</s>
<s>
Although_CS the_AT findings_NN2 of_IO these_DD2 studies_NN2 demonstrate_VV0 clearly_RR the_AT reduction_NN1 in_II transfusion_NN1 ,_, and_CC are_VBR stronger_JJR than_CSN the_AT findings_NN2 in_II liver/liver_NN1 transplantation_NN1 surgery_NN1 ,_, various_JJ modifications_NN2 of_IO the_AT basic_JJ test_NN1 are_VBR used_VVN ,_, introducing_VVG a_AT1 degree_NN1 of_IO variability_NN1 between_II assays_NN2 not_XX present_JJ with_IW normal_JJ coagulation_NN1 tests_NN2 ._. 
</s>
<s>
The_AT most_RGT common_JJ modification_NN1 used_VVN is_VBZ that_DD1 of_IO heparinase-coated_JJ testing_NN1 cups_NN2 described_VVN earlier_RRR ,_, but_CCB other_JJ modifications_NN2 have_VH0 been_VBN reported_VVN (_( Luddington_NP1 2005_MC )_) ._. 
</s>
<s>
This_DD1 variability_NN1 causes_VVZ difficulties_NN2 in_II assessing_VVG the_AT sensitivity_NN1 ,_, specificity_NN1 and_CC utility_NN1 of_IO TEG_NN1 as_II a_AT1 whole_NN1 ,_, as_CSA each_DD1 variation_NN1 is_VBZ almost_RR like_II a_AT1 different_JJ diagnostic_JJ test_NN1 ._. 
</s>
<s>
In_II all_DB clinical_JJ areas_NN2 ,_, haemostasis_NN1 must_VM be_VBI achieved_VVN with_IW minimal_JJ risk_NN1 to_II the_AT patient_NN1 ._. 
</s>
<s>
The_AT well_NN1 documented_VVD risks_NN2 of_IO transfusion_NN1 ,_, such_II21 as_II22 transfusion_NN1 reaction_NN1 or_CC infection_NN1 (_( Blood_NN1 Transfusion_NN1 Service_NN1 2001_MC ,_, SHoT_VVD 2003_MC )_) ,_, have_VH0 been_VBN joined_VVN in_II the_AT public_JJ perception_NN1 by_II the_AT small_JJ but_CCB possible_JJ risk_NN1 of_IO transmission_NN1 of_IO variant_NN1 Creutzfeldt-Jacob_NP1 Disease_NN1 (_( vCJD_NNU )_) ._. 
</s>
<s>
This_DD1 has_VHZ had_VHN an_AT1 impact_NN1 on_II transfusion_NN1 service_NN1 provision_NN1 in_II the_AT UK_NP1 ,_, most_RGT notably_RR resulting_VVG in_II leukocyte_NN1 depletion_NN1 of_IO blood_NN1 for_IF transfusion_NN1 (_( introduced_VVN in_II 1998-1999_MCMC )_) ,_, which_DDQ has_VHZ increased_VVN the_AT financial_JJ burden_NN1 of_IO sourcing_VVG transfusion_NN1 products_NN2 ._. 
</s>
<s>
In_RR21 addition_RR22 ,_, the_AT donor_NN1 pool_NN1 is_VBZ decreasing_JJ as_CSA screening_NN1 becomes_VVZ more_RGR stringent_JJ and_CC exclusive_JJ ,_, and_CC is_VBZ only_RR likely_JJ to_TO become_VVI more_RGR so_RR ._. 
</s>
<s>
Consequently_RR ,_, in_II31 addition_II32 to_II33 the_AT small_JJ but_CCB possible_JJ risks_NN2 of_IO transfusion_NN1 increasing_VVG ,_, the_AT decreased_JJ availability_NN1 of_IO products_NN2 for_IF transfusion_NN1 and_CC their_APPGE increased_JJ cost_NN1 demands_VVZ that_CST clinicians_NN2 must_VM find_VVI means_NN to_TO avoid_VVI transfusion_NN1 if_CS at_RR21 all_RR22 possible_JJ ,_, whilst_CS not_XX compromising_VVG the_AT health_NN1 and_CC well_RR being_VBG of_IO their_APPGE patients_NN2 ._. 
</s>
<s>
In_II practical_JJ terms_NN2 in_II the_AT perioperative_JJ field_NN1 ,_, this_DD1 means_VVZ both_RR minimising_VVG blood_NN1 loss_NN1 and_CC careful_JJ monitoring_NN1 to_TO anticipate_VVI the_AT potential_NN1 for_IF bleeding_VVG before_CS it_PPH1 occurs_VVZ and_CC treating_VVG the_AT imbalance_NN1 proactively_RR and_CC pharmacologically_RR if_CS possible_JJ ._. 
</s>
<s>
Thus_RR ,_, any_DD tool_NN1 which_DDQ demonstrates_VVZ an_AT1 ability_NN1 to_TO reduce_VVI peri-operative_JJ transfusion_NN1 requirements_NN2 is_VBZ welcomed_VVN enthusiastically_RR by_II clinicians_NN2 ._. 
</s>
<s>
Despite_II the_AT evidence_NN1 that_CST TEG_NP1 can_VM be_VBI used_VVN in_II practice_NN1 to_TO reduce_VVI unnecessary_JJ transfusion_NN1 of_IO blood_NN1 products_NN2 ,_, the_AT results_NN2 it_PPH1 produces_VVZ have_VH0 not_XX yet_RR been_VBN fully_RR validated_VVN in_II the_AT way_NN1 that_CST is_VBZ mandatory_JJ for_IF conventional_JJ coagulation_NN1 tests_NN2 (_( Intra_NP1 and_CC inter-observer_JJ variability_NN1 ,_, repeatability_NN1 ,_, calibrations_NN2 ,_, quality_NN1 controls_VVZ )_) (_( Samama_NP1 &;_NULL Ozier_NP1 2003_MC )_) ._. 
</s>
<s>
Most_DAT published_JJ studies_NN2 are_VBR by_II clinicians_NN2 rather_II21 than_II22 haematologists_NN2 ;_; Samama_NP1 &;_NULL Ozier_NP1 (_( 2003_MC )_) report_NN1 reluctance_NN1 from_II biologists_NN2 to_TO support_VVI the_AT use_NN1 of_IO point-of-care_JJ tests_NN2 and_CC point_VV0 out_RP that_CST none_PN have_VH0 yet_RR been_VBN accepted_VVN by_II the_AT experts_NN2 of_IO the_AT International_JJ Society_NN1 on_II Thrombosis_NN1 and_CC Haemostasis_NP1 ._. 
</s>
<s>
Manspeizer_NP1 et_RA21 al_RA22 (_( 2001_MC )_) found_VVD significant_JJ differences_NN2 in_II TEG_NP1 results_NN2 obtained_VVN from_II the_AT same_DA patients_NN2 when_RRQ venous_JJ as_CSA opposed_VVN to_II arterial_JJ blood_NN1 was_VBDZ used_VVN ,_, although_CS only_RR a_AT1 small_JJ number_NN1 (_( 40_MC )_) of_IO patients_NN2 were_VBDR used_VVN to_TO produce_VVI a_AT1 large_JJ (_( 134_MC )_) number_NN1 of_IO pairs_NN2 of_IO samples_NN2 ._. 
</s>
<s>
In_RR21 addition_RR22 ,_, provided_CS the_AT clinician_NN1 is_VBZ aware_JJ of_IO this_DD1 potential_NN1 for_IF variability_NN1 and_CC uses_VVZ only_RR one_MC1 type_NN1 of_IO sample_NN1 ,_, this_DD1 should_VM not_XX be_VBI a_AT1 problem_NN1 clinically_RR ._. 
</s>
<s>
A_AT1 standard_JJ operating_NN1 procedure_NN1 for_IF sample_NN1 taking_VVG and_CC processing_VVG in_II31 conjunction_II32 with_II33 thorough_JJ staff_NN training_NN1 would_VM minimise_VVI user_NN1 error_NN1 and_CC inter-user_JJ variability_NN1 ._. 
</s>
<s>
Luddington_NP1 (_( 2005_MC )_) commented_VVD that_CST several_DA2 studies_NN2 (_( Camenzind_NP1 et_RA21 al_RA22 ,_, 200_MC ;_; Vig_NP1 et_RA21 al_RA22 ,_, 2001_MC ,_, Rajwal_NP1 ,_, Richards_NP1 &;_NULL O'Meara_NP1 2004_MC )_) have_VH0 reported_VVN problems_NN2 with_IW sample_NN1 stability_NN1 ,_, but_CCB these_DD2 have_VH0 all_RR referred_VVN to_II blood_NN1 that_CST has_VHZ been_VBN citrated_VVN ,_, something_PN1 that_CST is_VBZ only_RR necessary_JJ for_IF the_AT laboratory_NN1 because_II21 of_II22 the_AT delay_NN1 in_II testing_NN1 ._. 
</s>
<s>
Vig_VV0 et_RA21 al_RA22 (_( 2001_MC )_) found_VVD that_CST a_AT1 rest_NN1 time_NNT1 of_IO 30_MC minutes_NNT2 was_VBDZ required_VVN between_II sample_NN1 taking_VVG and_CC testing_VVG to_TO ensure_VVI stability_NN1 ._. 
</s>
<s>
When_CS using_VVG TEG_NN1 within_II the_AT clinical_JJ area_NN1 'at_NN1 the_AT bedside'_NN1 as_CSA it_PPH1 is_VBZ intended_VVN ,_, this_DD1 ceases_VVZ to_TO be_VBI an_AT1 issue_NN1 ,_, and_CC in_II fact_NN1 having_VHG a_AT1 rest_NN1 period_NN1 takes_VVZ away_RL the_AT TEG_NP1 's_GE advantage_NN1 of_IO rapid_JJ testing_NN1 of_IO haemostasis_NN1 ._. 
</s>
<s>
Concerns_NN2 raised_VVN over_II variation_NN1 occurring_VVG with_IW repeat_VV0 sampling_VVG from_II one_MC1 sample_NN1 of_IO blood_NN1 (_( Vig_NP1 et_RA21 al_RA22 2001_MC ,_, Zambruni_NP1 et_RA21 al_RA22 2004_MC )_) are_VBR also_RR only_RR a_AT1 problem_NN1 in_II the_AT research_NN1 laboratory_NN1 ;_; in_II clinical_JJ practice_NN1 ,_, another_DD1 fresh_JJ sample_NN1 would_VM be_VBI taken_VVN ._. 
</s>
<s>
Rajwal_NN1 ,_, Richards_NP1 &;_NULL O'Meara_NP1 (_( 2004_MC )_) were_VBDR studying_VVG the_AT use_NN1 of_IO TEG_NN1 in_II children_NN2 ;_; in_II my_APPGE clinical_JJ practice_NN1 it_PPH1 is_VBZ requested_VVN only_RR for_IF adult_NN1 patients_NN2 (_( at_RR21 present_RR22 )_) and_CC so_RR variability_NN1 between_II adults_NN2 and_CC children_NN2 is_VBZ not_XX currently_RR a_AT1 concern_NN1 ._. 
</s>
<s>
The_AT lack_NN1 of_IO standardization_NN1 of_IO TEG_NP1 analysis_NN1 between_II centres_NN2 is_VBZ likely_JJ to_TO be_VBI an_AT1 increasing_JJ problem_NN1 as_II the_AT technique_NN1 is_VBZ continually_RR being_VBG diversified_VVN to_TO meet_VVI the_AT needs_NN2 of_IO different_JJ patient_JJ groups_NN2 and_CC for_IF research_NN1 ._. 
</s>
<s>
In_RR21 addition_RR22 ,_, an_AT1 alternative_JJ instrument_NN1 called_VVN the_AT ROTEM_NP1 (_( Sysmex_NP1 ,_, UK_NP1 )_) is_VBZ available_JJ ,_, which_DDQ uses_VVZ the_AT same_DA principles_NN2 as_CSA the_AT TEG_NN1 ._. 
</s>
<s>
Consequently_RR ,_, when_CS reviewing_VVG the_AT literature_NN1 it_PPH1 is_VBZ important_JJ to_TO ascertain_VVI which_DDQ instrument_NN1 was_VBDZ used_VVN and_CC whether_CSW any_DD modifications_NN2 were_VBDR made_VVN ._. 
</s>
<s>
Only_RR two_MC studies_NN2 directly_RR comparing_VVG TEG_NN1 with_IW common_JJ coagulation_NN1 tests_NN2 were_VBDR found_VVN ,_, Zuckerman_NP1 et_RA21 al_RA22 (_( 1981_MC )_) and_CC Avidan_NP1 et_RA21 al_RA22 (_( 2004_MC )_) ._. 
</s>
<s>
Zuckerman_NP1 et_RA21 al_RA22 (_( 1981_MC )_) compared_VVD the_AT abilities_NN2 of_IO TEG_NP1 and_CC the_AT group_NN1 of_IO six_MC commonly_RR used_JJ tests_NN2 (_( haematocrit_VV0 ,_, platelet_NN1 count_NN1 ,_, PTT_NP1 ,_, APTT_NP1 ,_, fibrinogen_NN1 &;_NULL fibrin_NN1 split_NN1 products_NN2 )_) to_TO detect_VVI blood_NN1 clotting_VVG abnormalities_NN2 ._. 
</s>
<s>
This_DD1 was_VBDZ a_AT1 fairly_RR large_JJ and_CC thorough_JJ study_NN1 ,_, using_VVG native_JJ blood_NN1 samples_NN2 for_IF TEG_NN1 analysis_NN1 within_II the_AT same_DA time_NNT1 frame_NN1 as_CSA with_IW clinical_JJ practice_NN1 ._. 
</s>
<s>
After_CS statistical_JJ analysis_NN1 ,_, it_PPH1 was_VBDZ found_VVN that_CST there_EX was_VBDZ a_AT1 strong_JJ relationship_NN1 between_II the_AT TEG_NN1 variables_NN2 and_CC the_AT group_NN1 of_IO coagulation_NN1 tests_NN2 ._. 
</s>
<s>
The_AT TEG_NN1 was_VBDZ reported_VVN to_TO be_VBI more_RGR sensitive_JJ to_II detection_NN1 of_IO clotting_VVG abnormalities_NN2 both_RR because_CS it_PPH1 measured_VVD the_AT interaction_NN1 between_II all_DB the_AT components_NN2 of_IO the_AT haemostatic_JJ system_NN1 ,_, unlike_II the_AT conventional_JJ tests_NN2 which_DDQ measure_VV0 plasma_NN1 ,_, and_CC because_CS it_PPH1 measures_VVZ the_AT whole_JJ process_NN1 of_IO clot_NN1 formation_NN1 ._. 
</s>
<s>
Against_II the_AT TEG_NN1 ,_, Zuckerman_NP1 et_RA21 al_RA22 (_( 1981_MC )_) did_VDD comment_VVI on_II the_AT marked_JJ differences_NN2 in_II interpretation_NN1 found_VVN by_II previous_JJ studies_NN2 ;_; this_DD1 is_VBZ no_RR21 longer_RR22 an_AT1 issue_NN1 because_CS the_AT modern_JJ instrument_NN1 has_VHZ much_RR higher_JJR quality_NN1 print-outs_NN2 and_CC computer_NN1 software_NN1 to_TO measure_VVI and_CC automatically_RR interpret_VVI results_NN2 ._. 
</s>
<s>
The_AT second_MD study_NN1 ,_, by_II Avidan_NP1 et_RA21 al_RA22 (_( 2004_MC )_) does_VDZ not_XX directly_RR compare_VVI TEG_NP1 and_CC routine_NN1 laboratory_NN1 tests_NN2 in_II31 terms_II32 of_II33 the_AT qualities_NN2 of_IO the_AT assays_NN2 themselves_PPX2 ,_, but_CCB as_II part_NN1 of_IO structured_JJ algorithms_NN2 to_TO manage_VVI bleeding_VVG after_II cardiac_JJ surgery_NN1 ._. 
</s>
<s>
This_DD1 used_VVD a_AT1 reasonable_JJ size_NN1 of_IO patient_JJ group_NN1 (_( 102_MC )_) ,_, but_CCB in_II31 addition_II32 to_II33 the_AT TEG_NN1 also_RR used_VVD three_MC other_JJ point-of-care_JJ instruments_NN2 ._. 
</s>
<s>
The_AT study_NN1 found_VVD that_CST using_VVG a_AT1 test-guided_JJ algorithm_NN1 reduced_VVD blood/blood_NN1 product_NN1 transfusion_NN1 when_CS compared_VVN with_IW clinical_JJ judgment_NN1 alone_RR ,_, but_CCB found_VVD no_AT advantage_NN1 of_IO either_RR the_AT laboratory-test_JJ guided_JJ algorithm_NN1 or_CC the_AT point-of-care_JJ test_NN1 guided_JJ algorithm_NN1 over_II one_PPX121 another_PPX122 ._. 
</s>
<s>
This_DD1 would_VM seem_VVI to_TO support_VVI the_AT use_NN1 of_IO test-guided_JJ algorithms_NN2 for_IF blood_NN1 product_NN1 usage_NN1 but_CCB does_VDZ not_XX provide_VVI any_DD more_DAR information_NN1 about_II the_AT benefits_NN2 or_CC otherwise_RR of_IO TEG_NN1 ._. 
</s>
<s>
It_PPH1 is_VBZ difficult_JJ to_TO directly_RR compare_VVI the_AT TEG_NN1 with_IW conventional_JJ coagulation_NN1 tests_NN2 as_CSA they_PPHS2 are_VBR so_RG different_JJ ,_, but_CCB it_PPH1 would_VM seem_VVI more_DAR studies_NN2 doing_VDG this_DD1 need_NN1 to_TO be_VBI carried_VVN out_RP ,_, particularly_RR in_II31 light_II32 of_II33 the_AT massive_JJ improvements_NN2 in_II technology_NN1 and_CC the_AT increase_NN1 in_II use_NN1 of_IO the_AT instrument_NN1 over_II the_AT last_MD ten_MC years_NNT2 ._. 
</s>
<s>
A_AT1 meta-analysis_NN1 of_IO the_AT results_NN2 of_IO published_JJ studies_NN2 would_VM also_RR be_VBI useful_JJ in_II assessing_VVG the_AT utility_NN1 of_IO the_AT TEG_NN1 ,_, although_CS this_DD1 may_VM be_VBI difficult_JJ because_II21 of_II22 the_AT number_NN1 of_IO modifications_NN2 to_II the_AT test_NN1 currently_RR in_II use_NN1 ._. 
</s>
<s>
Another_DD1 issue_NN1 which_DDQ must_VM be_VBI kept_VVN in_II mind_NN1 is_VBZ that_DD1 of_IO cost_NN1 ._. 
</s>
<s>
I_PPIS1 have_VH0 already_RR discussed_VVN the_AT finance_NN1 issues_NN2 around_II transfusion_NN1 ,_, but_CCB there_EX is_VBZ also_RR the_AT cost_NN1 of_IO the_AT tests_NN2 themselves_PPX2 ._. 
</s>
<s>
I_PPIS1 did_VDD not_XX find_VVI any_DD discussion_NN1 of_IO this_DD1 in_II the_AT literature_NN1 ,_, but_CCB it_PPH1 seems_VVZ reasonable_JJ that_CST the_AT lack_NN1 of_IO processing_NN1 ,_, transport_NN1 and_CC laboratory_NN1 staff_NN required_VVN for_IF TEG_NN1 would_VM reduce_VVI the_AT cost_NN1 ,_, although_CS the_AT initial_JJ set-up_NN1 is_VBZ likely_JJ to_TO be_VBI expensive_JJ ._. 
</s>
<s>
In_RR21 addition_RR22 maintenance_NN1 of_IO the_AT equipment_NN1 ,_, including_II calibration_NN1 and_CC quality_NN1 control_NN1 ,_, would_VM be_VBI required_VVN ._. 
</s>
<s>
There_EX can_VM be_VBI no_AT disagreement_NN1 that_CST a_AT1 reduction_NN1 in_II the_AT use_NN1 of_IO blood_NN1 and_CC blood_NN1 products_NN2 during_II surgery_NN1 is_VBZ needed_VVN ,_, from_II a_AT1 patient_JJ safety_NN1 ,_, resource_VV0 management_NN1 and_CC financial_JJ concern_NN1 ._. 
</s>
<s>
There_EX is_VBZ a_AT1 great_JJ deal_NN1 of_IO evidence_NN1 that_CST TEG_NP1 has_VHZ been_VBN used_VVN to_TO achieve_VVI this_DD1 in_II cardiac_JJ surgery_NN1 ,_, which_DDQ is_VBZ estimated_VVN to_TO use_VVI 20%_NNU of_IO the_AT UK_NP1 blood_NN1 supply_NN1 (_( Anderson_NP1 et_RA21 al_RA22 2006_MC )_) and_CC so_RR it_PPH1 is_VBZ reasonable_JJ that_CST it_PPH1 could_VM also_RR be_VBI of_IO use_NN1 in_II general_JJ surgery_NN1 ._. 
</s>
<s>
The_AT rapidity_NN1 with_IW which_DDQ a_AT1 result_NN1 can_VM be_VBI obtained_VVN would_VM be_VBI a_AT1 massive_JJ improvement_NN1 over_II the_AT wait_NN1 for_IF laboratory_NN1 tests_NN2 of_IO coagulation_NN1 ,_, which_DDQ I_PPIS1 have_VH0 found_VVN in_II my_APPGE practice_NN1 can_VM easily_RR be_VBI an_AT1 hour_NNT1 ._. 
</s>
<s>
With_IW surgery_NN1 such_II21 as_II22 aortic_JJ aneurysm_NN1 repair_NN1 ,_, where_CS massive_JJ volumes_NN2 of_IO blood_NN1 can_VM be_VBI lost_VVN and_CC infusions_NN2 given_VVN in_II minutes_NNT2 ,_, by_II the_AT time_NNT1 a_AT1 result_NN1 is_VBZ obtained_VVN it_PPH1 is_VBZ irrelevant_JJ ,_, and_CC consequently_RR transfusion_NN1 decisions_NN2 are_VBR based_VVN on_II clinical_JJ judgment_NN1 or_CC ratio_NN1 (_( i.e._REX four_MC units_NN2 of_IO fresh_JJ frozen_JJ plasma_NN1 given_VVN to_II each_DD1 six_MC units_NN2 of_IO packed_JJ red_JJ cells_NN2 )_) ._. 
</s>
<s>
The_AT assertion_NN1 by_II Avidan_NP1 et_RA21 al_RA22 (_( 2004_MC )_) that_DD1 transfusion_NN1 should_VM be_VBI based_VVN on_II a_AT1 laboratory-test_JJ guided_JJ algorithm_NN1 is_VBZ not_XX necessarily_RR achievable_JJ in_II the_AT operating_NN1 theatre_NN1 ,_, both_RR because_II21 of_II22 the_AT time_NNT1 for_IF testing_VVG and_CC difficulty_NN1 transporting_VVG samples_NN2 to_II the_AT laboratory_NN1 ._. 
</s>
<s>
Although_CS not_XX yet_RR validated_VVD ,_, the_AT use_NN1 of_IO TEG_NN1 to_TO guide_VVI transfusion_NN1 would_VM be_VBI an_AT1 evidence-based_JJ improvement_NN1 in_II patient_NN1 care_NN1 and_CC would_VM hopefully_RR reduce_VVI unnecessary_JJ transfusions_NN2 ._. 
</s>
<s>
As_II a_AT1 scientific_JJ test_NN1 ,_, TEG_NP1 needs_VVZ to_TO be_VBI more_RGR thoroughly_RR tested_VVN to_TO assess_VVI repeatability_NN1 ,_, variability_NN1 etc_RA ,_, to_TO establish_VVI accepted_JJ methods_NN2 of_IO quality_NN1 control_NN1 and_CC calibration_NN1 and_CC to_TO develop_VVI consistency_NN1 between_II different_JJ centres_NN2 ._. 
</s>
<s>
However_RR ,_, its_APPGE sensitivity_NN1 for_IF detection_NN1 of_IO coagulation_NN1 abnormalities_NN2 is_VBZ high_JJ (_( Zuckerman_NP1 et_NP1 a_AT1 1981_MC )_) and_CC the_AT evidence_NN1 for_IF its_APPGE use_NN1 to_TO guide_VVI transfusion_NN1 requirements_NN2 is_VBZ strong_JJ ._. 
</s>
<s>
Conventional_JJ laboratory_NN1 tests_NN2 for_IF coagulation_NN1 continue_VV0 to_TO be_VBI the_AT 'gold_NN1 standard'_NN1 but_CCB point-of-care_JJ tests_NN2 such_II21 as_II22 TEG_NP1 have_VH0 a_RR21 lot_RR22 to_II offer_NN1 to_TO improve_VVI patient_NN1 care_NN1 ._. 
</s>
<s>
I_PPIS1 believe_VV0 that_CST the_AT use_NN1 of_IO TEG_NN1 in_II my_APPGE clinical_JJ area_NN1 is_VBZ justified_VVN ,_, and_CC if_CS the_AT introduction_NN1 of_IO the_AT test_NN1 was_VBDZ carried_VVN out_RP with_IW the_AT co-operation_NN1 and_CC support_NN1 of_IO the_AT haematology_NN1 and_CC blood_NN1 transfusion_NN1 departments_NN2 many_DA2 of_IO the_AT potential_JJ problems_NN2 could_VM be_VBI avoided_VVN ._. 
</s>
<s>
In_RR21 addition_RR22 ,_, the_AT widespread_JJ introduction_NN1 of_IO other_JJ measures_NN2 such_II21 as_II22 perioperative_JJ red_JJ cell_NN1 salvage_NN1 ,_, autologous_JJ pre-donation_NN1 and_CC other_JJ point-of-care_JJ coagulation_NN1 monitoring_NN1 (_( such_II21 as_II22 platelet_NN1 function_NN1 monitoring_NN1 ,_, activated_VVD clotting_VVG time_NNT1 and_CC others_NN2 )_) is_VBZ likely_JJ to_TO bring_VVI about_RP a_AT1 significant_JJ reduction_NN1 in_II the_AT transfusion_NN1 of_IO blood_NN1 and_CC blood_NN1 products_NN2 and_CC thus_RR both_RR improve_VV0 the_AT patient_JJ experience_NN1 and_CC reduce_VV0 the_AT financial_JJ burden_NN1 within_II the_AT perioperative_JJ setting_NN1 ._. 
</s>
<s>
The_AT introduction_NN1 of_IO some_DD form_NN1 of_IO guided_JJ protocol_NN1 for_IF perioperative_JJ transfusion_NN1 seems_VVZ both_RR desirable_JJ and_CC inevitable_JJ ;_; the_AT tests_NN2 which_DDQ will_VM guide_VVI it_PPH1 remain_VV0 to_TO be_VBI seen_VVN ._. 
</s>
